Literature DB >> 16758266

Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease.

A Tavridou1, A Efthimiadis, I Efthimiadis, H Paschalidou.   

Abstract

OBJECTIVE: The aim of the present study was to determine the effect of simvastatin on the levels of oxidized low-density lipoprotein (ox-LDL) and free radicals in hypercholesterolemic subjects undergoing primary and secondary prevention of coronary heart disease (CHD).
METHODS: Fifteen subjects with hypercholesterolemia and no obvious CHD and 29 subjects with hypercholesterolemia and stable angina received 40 mg of simvastatin daily for 12 weeks. Serum total cholesterol, HDL-cholesterol and triglyceride concentrations were determined by automated enzymatic assays whereas LDL-cholesterol was calculated using the Friedwald formula. The ox-LDL levels were determined by a commercially available ELISA kit. Free radicals were assessed by the Free Radical Analytical System (FRAS).
RESULTS: Both in primary and secondary prevention, subjects had borderline levels of free radicals but in neither group there was a significant reduction of free radicals after simvastatin treatment. In subjects undergoing primary prevention of CHD, ox-LDL levels were reduced by 31.1+/-5.0% (P < 0.001) whereas in secondary prevention were reduced by 6.5+/-5.2% (P < 0.02) after simvastatin treatment. The reduction of ox-LDL levels did not correlate with the reduction of total cholesterol levels in either group studied. In both groups, ox-LDL levels were not associated with free radical levels either before or after simvastatin treatment.
CONCLUSION: This study demonstrates that simvastatin can significantly reduce circulating ox-LDL levels both in subjects undergoing primary and secondary prevention of CHD. These results could partly explain the slowing down of the progression of atherosclerosis caused by HMG-CoA reductase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16758266     DOI: 10.1007/s00228-006-0097-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

Review 1.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

2.  Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men.

Authors:  K Wallenfeldt; B Fagerberg; J Wikstrand; J Hulthe
Journal:  J Intern Med       Date:  2004-11       Impact factor: 8.989

3.  Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients.

Authors:  Teruo Inoue; Masatoshi Hayashi; Kan Takayanagi; Shigenori Morooka
Journal:  Atherosclerosis       Date:  2002-02       Impact factor: 5.162

4.  Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia.

Authors:  Susumu Sasaki; Noriko Kuwahara; Keiko Kunitomo; Sanae Harada; Takashi Yamada; Akihiro Azuma; Kazuo Takeda; Masao Nakagawa
Journal:  Am J Cardiol       Date:  2002-02-15       Impact factor: 2.778

5.  Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.

Authors:  Aina Hognestad; Pål Aukrust; Ragnhild Wergeland; Oddvar Stokke; Lars Gullestad; Anne Grete Semb; Torbjørn Holm; Arne K Andreassen; John K Kjekshus
Journal:  Clin Cardiol       Date:  2004-04       Impact factor: 2.882

6.  Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients.

Authors:  Koichi Sakabe; Nobuo Fukuda; Katsunori Wakayama; Teru Nada; Hisanori Shinohara; Yoshiyuki Tamura
Journal:  Circ J       Date:  2003-10       Impact factor: 2.993

Review 7.  Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities.

Authors:  Robert S Rosenson
Journal:  Atherosclerosis       Date:  2004-03       Impact factor: 5.162

8.  Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.

Authors:  Judith M van den Akker; Sebastian J H Bredie; Sabine H A Diepenveen; Lambertus J H van Tits; Anton F H Stalenhoef; Rob van Leusen
Journal:  J Nephrol       Date:  2003 Mar-Apr       Impact factor: 3.902

9.  Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.

Authors:  P Holvoet; J Vanhaecke; S Janssens; F Van de Werf; D Collen
Journal:  Circulation       Date:  1998-10-13       Impact factor: 29.690

10.  A comparative study of the in vitro antioxidant activity of statins.

Authors:  Ferdinando Franzoni; Alfredo Quiñones-Galvan; Francesco Regoli; Ele Ferrannini; Fabio Galetta
Journal:  Int J Cardiol       Date:  2003-08       Impact factor: 4.164

View more
  7 in total

1.  ATP-dependent potassium channels are implicated in simvastatin pretreatment-induced inhibition of apoptotic cell death after renal ischemia/reperfusion injury.

Authors:  Kamran Dowlatshahi; Marjan Ajami; Hamidreza Pazoki-Toroudi; Seyed Javad Hajimiresmaiel
Journal:  Med J Islam Repub Iran       Date:  2015-03-14

Review 2.  Niacin extended-release/simvastatin.

Authors:  Mark Sanford; Monique P Curran
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Oxidized LDL and the metabolic syndrome.

Authors:  Paul Holvoet; Dieuwke De Keyzer; David R Jacobs
Journal:  Future Lipidol       Date:  2008-12

4.  Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin.

Authors:  Osamah Hussein; Lilia Minasian; Yaroslav Itzkovich; Karina Shestatski; Lizora Solomon; Jamal Zidan
Journal:  Br J Clin Pharmacol       Date:  2008-01-30       Impact factor: 4.335

5.  The Fungal Iron Chelator Desferricoprogen Inhibits Atherosclerotic Plaque Formation.

Authors:  László Potor; Sikura Katalin Éva; Hajnalka Hegedűs; Dávid Pethő; Zsuzsa Szabó; Zsuzsa M Szigeti; István Pócsi; György Trencsényi; Dezső Szikra; Ildikó Garai; Tamás Gáll; Zsolt Combi; János Kappelmayer; György Balla; József Balla
Journal:  Int J Mol Sci       Date:  2020-07-03       Impact factor: 5.923

6.  The effect of atorvastatin treatment duration on oxidative stress markers and lipid profile in patients with coronary artery diseases: A case series study.

Authors:  Gholamreza Shahsavari; Amir Raoufi; Aram Toolabi; Nahid Hosseninejadmir; Hassan Ahmadvand; Mehdi Safariebrahimsarabie
Journal:  ARYA Atheroscler       Date:  2017-11

Review 7.  Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease.

Authors:  Shen Gao; Jing Liu
Journal:  Chronic Dis Transl Med       Date:  2017-05-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.